Wall Street analysts forecast that Perrigo Company (NYSE:PRGO) will report $1.24 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Thirteen analysts have issued estimates for Perrigo’s earnings. The highest sales estimate is $1.28 billion and the lowest is $1.21 billion. Perrigo reported sales of $1.33 billion during the same quarter last year, which indicates a negative year-over-year growth rate of 6.8%. The firm is scheduled to report its next earnings results on Monday, May 28th.

According to Zacks, analysts expect that Perrigo will report full year sales of $1.24 billion for the current year, with estimates ranging from $4.84 billion to $4.92 billion. For the next fiscal year, analysts anticipate that the business will report sales of $5.00 billion per share, with estimates ranging from $4.88 billion to $5.10 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Perrigo.

Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, November 9th. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.28. Perrigo had a positive return on equity of 11.60% and a negative net margin of 26.28%. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business earned $1.65 EPS. Perrigo’s quarterly revenue was down 2.0% compared to the same quarter last year.

A number of equities analysts recently issued reports on PRGO shares. Royal Bank of Canada upgraded Perrigo from an “underperform” rating to a “sector perform” rating and increased their target price for the stock from $64.00 to $86.00 in a report on Friday, November 10th. Jefferies Group set a $71.00 target price on Perrigo and gave the stock a “hold” rating in a report on Sunday, October 29th. UBS Group reiterated a “buy” rating and issued a $98.00 target price (up from $84.00) on shares of Perrigo in a report on Thursday, October 5th. Cantor Fitzgerald set a $107.00 target price on Perrigo and gave the stock a “buy” rating in a report on Saturday, December 16th. Finally, Oppenheimer started coverage on Perrigo in a report on Monday, October 2nd. They issued a “buy” rating and a $88.00 target price on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $92.00.

Perrigo (PRGO) opened at $91.80 on Monday. Perrigo has a twelve month low of $63.68 and a twelve month high of $92.75. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.72 and a quick ratio of 1.24. The stock has a market capitalization of $12,929.20, a price-to-earnings ratio of -10.02, a P/E/G ratio of 1.94 and a beta of 0.70.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 19th. Shareholders of record on Friday, December 1st were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend was Thursday, November 30th. Perrigo’s dividend payout ratio (DPR) is presently -6.99%.

In other news, EVP John Wesolowski sold 450 shares of Perrigo stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $83.09, for a total transaction of $37,390.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Todd W. Kingma sold 1,500 shares of Perrigo stock in a transaction on Friday, December 28th. The stock was sold at an average price of $88.52, for a total value of $132,780.00. Following the sale, the vice president now owns 19,565 shares in the company, valued at $1,731,893.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,051 shares of company stock worth $355,370. Company insiders own 6.90% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRGO. JPMorgan Chase & Co. raised its stake in shares of Perrigo by 14.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 83,822 shares of the company’s stock worth $6,331,000 after purchasing an additional 10,461 shares during the period. Commonwealth Bank of Australia raised its stake in shares of Perrigo by 13.8% during the 2nd quarter. Commonwealth Bank of Australia now owns 1,455 shares of the company’s stock worth $108,000 after purchasing an additional 176 shares during the period. Ameriprise Financial Inc. raised its stake in shares of Perrigo by 534.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 302,164 shares of the company’s stock worth $22,825,000 after purchasing an additional 254,565 shares during the period. Norinchukin Bank The raised its stake in shares of Perrigo by 6.8% during the 2nd quarter. Norinchukin Bank The now owns 9,950 shares of the company’s stock worth $751,000 after purchasing an additional 633 shares during the period. Finally, Nationwide Fund Advisors raised its stake in shares of Perrigo by 0.4% during the 2nd quarter. Nationwide Fund Advisors now owns 55,199 shares of the company’s stock worth $4,169,000 after purchasing an additional 200 shares during the period. Institutional investors own 83.29% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Perrigo Company (PRGO) Will Announce Quarterly Sales of $1.24 Billion” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/15/zacks-analysts-anticipate-perrigo-company-prgo-will-announce-quarterly-sales-of-1-24-billion-2.html.

About Perrigo

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Get a free copy of the Zacks research report on Perrigo (PRGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.